Form 8-K - Current report:
SEC Accession No. 0001641172-25-023296
Filing Date
2025-08-13
Accepted
2025-08-13 06:17:57
Documents
15
Period of Report
2025-08-12
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 41320
2 EX-99.1 ex99-1.htm EX-99.1 506424
3 GRAPHIC form8-k_001.jpg GRAPHIC 14734
  Complete submission text file 0001641172-25-023296.txt   847733

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cycc-20250812.xsd EX-101.SCH 3743
5 XBRL DEFINITION FILE cycc-20250812_def.xml EX-101.DEF 26581
6 XBRL LABEL FILE cycc-20250812_lab.xml EX-101.LAB 36613
7 XBRL PRESENTATION FILE cycc-20250812_pre.xml EX-101.PRE 25205
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5753
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 251208846
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)